<DOC>
	<DOC>NCT00777946</DOC>
	<brief_summary>This study will assess the safety and efficacy of combination aliskiren/amlodipine in patients not adequately controlled with aliskiren alone</brief_summary>
	<brief_title>Study to Evaluate the Efficacy and Safety of Combination Aliskiren/Amlodipine in Patients Not Adequately Responding to Aliskiren Alone</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Amlodipine</mesh_term>
	<criteria>Newly diagnosed patients or patients who have not been treated for hypertension within the 4 weeks prior to Visit 1 must have a mean sitting Diastolic Blood Pressure (msDBP) ≥ 95 mmHg and &lt; 110 mmHg at Visits 1 and 2 Patients who have been treated for hypertension within the 4 weeks prior to Visit 1 must have a msDBP ≥ 90 mmHg and &lt; 110 mmHg at Visit 2 All patients must have a msDBP ≥ 90 mmHg and &lt; 110 mmHg at Visit 4 Severe hypertension Pregnant or nursing (lactating) women Women of childbearing potential Previous or current diagnosis of heart failure New York Heart Association (NYHA Class IIIV) Serum potassium ≥ 5.3 mEq/L (mmol/L) at Visit 1 Uncontrolled Type 1 or Type 2 diabetes mellitus Hypersensitivity to renin inhibitors, calcium channel blockers, or to drugs with Similar chemical structures History of hypertensive encephalopathy or cerebrovascular accident, or history of transient ischemic attack (TIA), myocardial infarction, coronary bypass surgery, or any percutaneous coronary intervention Other protocoldefined inclusion/exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>Aliskiren, Amlodipine, Non-responder to aliskiren</keyword>
</DOC>